(Q43508949)

24 November 2017

title

In vitro and in vivo studies of AT-1362, a newly synthesized and orally active inhibitor of thrombin (English)

1 reference

24 November 2017

J Cho

1

1 reference

24 November 2017

H Seo

2

1 reference

24 November 2017

C Yun

3

1 reference

24 November 2017

B Koo

4

1 reference

24 November 2017

S Yoshida

5

1 reference

24 November 2017

T Koga

6

1 reference

24 November 2017

T Dan

7

1 reference

24 November 2017

H Kim

8

1 reference

24 November 2017

publication date

1 October 2000

1 reference

24 November 2017

1 reference

24 November 2017

volume

100

1 reference

24 November 2017

issue

1

1 reference

24 November 2017

page(s)

97-107

1 reference

New anticoagulant strategies. Current status and future potential

24 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Development of argatroban, a direct thrombin inhibitor, and its clinical application

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Selective inhibition of thrombin by (2R,4R)-4-methyl-1-[N2-[(3-methyl-1,2,3,4-tetrahydro-8-quinolinyl++ +) sulfonyl]-l-arginyl)]-2-piperidinecarboxylic acid

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Antithrombotic actions of argatroban in rat models of venous, 'mixed' and arterial thrombosis, and its effects on the tail transection bleeding time

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Antithrombotic activity of argatroban in experimental thrombosis in the rabbit

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Antithrombotic actions of the thrombin inhibitor, argatroban, in a canine model of coronary cyclic flow: comparison with heparin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Low-molecular-weight heparin (fragmin) and thrombin active-site inhibitor (argatroban) compared in experimental arterial and venous thrombosis and bleeding time

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

A multicenter, randomized study of argatroban versus heparin as adjunct to tissue plasminogen activator (TPA) in acute myocardial infarction: myocardial infarction with novastan and TPA (MINT) study

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

A Randomized, Blinded Study of Two Doses of Novastan(R) (Brand of Argatroban) Versus Heparin as Adjunctive Therapy to Recombinant Tissue Plasminogen Activator (Accelerated Administration) in Acute Myocardial Infarction: Rationale and Design of the M

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Determination of theophylline in plasma ultrafiltrate by reversed phase high pressure liquid chromatography

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

A new experimental model of venous thrombosis in rats involving partial stasis and slight endothelium alterations

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Rat model of arterial thrombosis induced by ferric chloride

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

The use of dihydroergotamine and heparin in the prophylaxis of deep venous thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Pathogenesis of venous thrombosis: a new insight

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Rat jugular vein hemostasis--a new model for testing antithrombotic agents

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Prevention of experimental venous thrombosis in rabbits with low molecular weight heparin, dextran and their combinations, administered before or during induction of venous endothelial trauma

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

A novel model of venous thrombosis in the vena cava of rabbits

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Prevention and treatment of venous thromboembolism

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Activated clotting time as an appropriate test to compare heparin and direct thrombin inhibitors such as hirudin or Ro 46-6240 in experimental arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Pathology of arterial thrombosis

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Effect of thrombin inhibitors on platelet functions: comparative analysis of DuP 714 and hirudin

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Characterization of in vitro and in vivo platelet responses to thrombin and thrombin receptor-activating peptides in guinea pigs

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

Guide to anticoagulant therapy. Part 2: Oral anticoagulants. American Heart Association

1 reference

https://api.crossref.org/works/10.1016%2FS0049-3848%2800%2900298-X

7 January 2021

10.1016/S0049-3848(00)00298-X

Identifiers

DOI

1 reference

24 November 2017

1 reference